StockData
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc. (AKBA) stock

AKBANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$0.40−0.05 (-10.74%)

Close on Nov 17, 2026Market cap $110.95MP/E –Yield –

Akebia Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Akebia Therapeutics's price to sales ratio was 0.7× on Nov 11, 2026, against 1.9× a year earlier. Over the last 5 years it ranged from 0.2× to 5.2×, with a median of 1.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20260.7×−1.2
2025Dec 31, 20251.9×−0.5
2024Dec 31, 20242.4×+1.2
2023Dec 29, 20231.2×+0.8
2022Dec 30, 20220.4×−1.5
2021Dec 31, 20211.9×+0.6
2020Dec 31, 20201.3×−1.0
2019Dec 31, 20192.3×+1.0
2018Dec 31, 20181.3×−330.2
2017Apr 28, 2017331.6×–

More Akebia Therapeutics figures

See a number that looks wrong?